Scalper1 News
Small biotech Achillion Pharmaceuticals (ACHN) announced late Tuesday that it had entered a collaboration with Johnson & Johnson (JNJ) to develop its hepatitis C drugs, potentially worth more than $1 billion. J&J agreed to invest $225 million in Achillion upfront, and promised up to $1.1 billion in development, regulatory and sales milestone payments if the companies successfully launch their pipeline of drugs treating the hepatitis C virus (HCV). Scalper1 News
Scalper1 News